Metronidazole (Flagyl IV, Searle)

Area of Science:

• Pharmacology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Metronidazole is a narrow-spectrum antibiotic effective against anaerobic bacteria.
• Resistance to metronidazole is uncommon.
• The drug achieves therapeutic concentrations in most body compartments via oral or intravenous administration.

Purpose of the Study:

• To evaluate the efficacy and safety of metronidazole as an antibiotic for anaerobic infections.
• To compare metronidazole with clindamycin and chloramphenicol.
• To assess the risks and benefits of metronidazole, including its potential carcinogenicity.

Main Methods:

• Clinical efficacy and side effect profiles were reviewed.
• Pharmacokinetic data on drug distribution were considered.
• Carcinogenicity data from animal studies and human follow-up were analyzed.

Main Results:

• Metronidazole demonstrates high efficacy against common anaerobes with unusual resistance.
• It is well-tolerated, with generally transient or reversible side effects.
• Metronidazole shows comparable efficacy to clindamycin and chloramphenicol, with advantages in CNS infections and no irreversible hematologic toxicities or pseudomembranous colitis.
• Animal studies indicate carcinogenicity, but human data show no increased cancer incidence in short-term follow-up.

Conclusions:

• Metronidazole is a valuable alternative to clindamycin and chloramphenicol for anaerobic infections, particularly in CNS infections or when other agents cause adverse effects.
• Despite carcinogenic potential in animals, the human risk appears small, though long-term data are pending.
• Conservative use of metronidazole is recommended until its long-term safety in humans is fully established.